In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.


Cenegermin is a medication belonging to the recombinant human nerve growth factor (rhNGF) class of drugs. This drug is utilized for the management of neurotrophic keratitis and is the first-ever topical biologic approved in the field of ophthalmology. In 2018, the U.S. Food and Drug Administration (FDA) approved the 0.002% ophthalmic solution of cenegermin. As a topical rhNGF, the drug demonstrates remarkable specificity for the anterior segment of the eye, playing a crucial role in supporting corneal innervation and maintaining its integrity. This activity thoroughly outlines the FDA-approved indications, action, and contraindications of cenegermin, positioning it as a valuable treatment for neurotrophic keratitis. Furthermore, this activity will highlight the mechanism of action, adverse event profile, and other essential factors of cenegermin, including dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions, which are crucial for the interprofessional team to manage neurotrophic keratitis in patients effectively. In addition, the activity provides clinicians with information on effectively managing toxicity in the event of an overdose during cenegermin administration.

Publication types

  • Study Guide